DelveInsight has introduced a new Report on “Benign prostatic hyperplasia (BPH) Pipeline Insight, 2020”.
“Benign prostatic hyperplasia (BPH) Pipeline Insight, 2020“ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Benign prostatic hyperplasia (BPH) market. A detailed picture of the Benign prostatic hyperplasia (BPH) pipeline landscape is provided, which includes the disease overview and Benign prostatic hyperplasia (BPH) treatment guidelines.
The assessment part of the report embraces in-depth Benign prostatic hyperplasia (BPH) commercial assessment and clinical assessment of the Benign prostatic hyperplasia (BPH) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Benign prostatic hyperplasia (BPH) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Drugs covered in the report are:-
There are several key players robustly involved in developing potential products such as
- GV1001
- Vibegron
- AUS-131 (S-equo)
- And Many Others
Key Players covered in the report are:-
- GemVax & KAEL
- Urovant Sciences
- Ausio Pharmaceuticals
- And many others
About the Disease:
Benign Prostatic Hyperplasia (BPH) is a noncancerous condition in men in which the prostate gland is enlarged. BPH is also called benign prostatic hypertrophy or benign prostatic obstruction.
The prostate goes through two main growth periods as a man ages. The first occurs early in puberty when the prostate doubles in size. The second phase of growth begins around age 25 and continues during most of a man’s life. BPH often occurs with the second growth phase.
The enlarged prostate gland presses against and pinches the urethra. The bladder wall becomes thicker. Ultimately the bladder may weaken and lose the ability to empty completely. The narrowing of the urethra and urinary retention causes many of the problems associated with BPH.
Need of frequent urination is a common symptom. Other symptoms include the feeling of full bladder even after urination, a week flow of urine, stop-start urination, difficulty in starting urination, and needing to get up frequently in the night to urinate.
The cause of BPH is not well understood; however, it is most common in old men. As BPH does not develop in men whose testicles were removed before puberty, some researchers believe factors related to aging and the testicles are the underlying causes.
Researchers also believe that a high proportion of estrogen within the prostate stimulates the activity of prostate cell growth factors. Another theory suggests that dihydrotestosterone (DHT) that plays a role in prostate development and growth may be the cause as it is found that men who do not produce DHT do not develop BPH.
Request for Sample Pages: https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-pipeline-insight
The diagnosis of BPH can be made by examining personal or family history, physical examination and medical tests. The American Urological Association (AUA) has built a BPH Symptom Score Index. It’s a series of questions about how often urinary symptoms happen.
The score rates BPH from mild to severe.
The tests for BPH include cystoscopy, post-void residual volume, prostate-specific antigen (PSA) blood test, ultrasound, urine test, uroflowmetry, urodynamic pressure, or Urinary blood test.
The treatment of BPH includes lifestyle changes, medications, minimally invasive procedures, and surgery.
Request for Sample Pages: https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-pipeline-insight
Table of Contents
- Report Introduction
- Benign prostatic hyperplasia (BPH)
- Benign prostatic hyperplasia (BPH) Current Treatment Patterns
- Benign prostatic hyperplasia (BPH) – DelveInsight’s Analytical Perspective
- Therapeutic Assessment
- Benign prostatic hyperplasia (BPH) Late Stage Products (Phase-III)
- Benign prostatic hyperplasia (BPH) Mid Stage Products (Phase-II)
- Early Stage Products (Phase-I)
- Pre-clinical Products and Discovery Stage Products
- Inactive Products
- Dormant Products
- Benign prostatic hyperplasia (BPH) Discontinued Products
- Benign prostatic hyperplasia (BPH) Product Profiles
- Benign prostatic hyperplasia (BPH) Key Companies
- Benign prostatic hyperplasia (BPH) Key Products
- Dormant and Discontinued Products
- Benign prostatic hyperplasia (BPH) Unmet Needs
- Benign prostatic hyperplasia (BPH) Future Perspectives
- Benign prostatic hyperplasia (BPH) Analyst Review
- Appendix
- Report Methodology
Related reports:
Benign prostatic hyperplasia (BPH) – Epidemiology Forecast to 2030
DelveInsight’s ‘Benign prostatic hyperplasia (BPH) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Benign prostatic hyperplasia (BPH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Benign prostatic hyperplasia (BPH)- Market Insight, Epidemiology and Market Forecast -2030
DelveInsight’s “Benign prostatic hyperplasia (BPH) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Benign prostatic hyperplasia (BPH), historical and forecasted epidemiology as well as the Benign prostatic hyperplasia (BPH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Contact us:
Shruti Thakur
info@delveinsight.com
+91-9650213330
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/